Introduction
============

Previous studies have indicated that, in lung cancers, the gene rearrangement of *ALK* is mutually exclusive with mutations in the epidermal growth factor receptor (*EGFR*) gene ([@b1-mco-0-0-1306]). However, the coexistence of *EML4-ALK* fusions and *EGFR* mutations (double positive) has been occasionally reported in a small proportion of patients ([@b2-mco-0-0-1306]--[@b27-mco-0-0-1306]). Currently, there is no consensus opinion regarding the treatment of these patients with double positive molecular alterations. The effectiveness of precision therapy also remains unknown. The present study reports the case of a 53-year-old woman with stage IV lung adenocarcinoma, who was treated with first-line chemotherapy with a regime of cisplatin (75 mg/m^2^) and pemetrexed (PEM) (500 mg/m^2^) every three weeks up to four cycles, followed by PEM maintenance therapy. As the disease progressed, the patient underwent a repeat biopsy, which revealed mutation of the *EGFR* as well as an *ALK* gene rearrangement. Gefitinib administration proved to be ineffective, although crizotinib revealed a partial response (PR). In addition, all the cases reported in the English literature of concomitant *EGFR* mutations with *ALK* gene rearrangement were reviewed.

Case report
===========

A 53-year-old female non-smoker was admitted to our hospital (The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China) for right chest discomfort in September 2013. A chest computed tomography (CT) scan revealed a 4.0×3.5 cm mass in the right upper lobe, with moderate pleural effusion ([Fig. 1](#f1-mco-0-0-1306){ref-type="fig"}). The patient underwent thoracentesis. The pleural effusion specimen revealed the presence of malignant cells, which were positive for thyroid transcription factor-1 and negative for p63, consistent with metastatic lung adenocarcinoma ([Fig. 2](#f2-mco-0-0-1306){ref-type="fig"}). *EGFR* mutational analysis was performed on the cell-block material using an amplification refractory mutation system (ARMS) technique (ADx-ARMS kit, Amoy Diagnostics, Xiamen, China). The experimental procedure followed, and data analysis performed, were precisely as described in the manufacturer\'s protocol. No *EGFR* mutations were identified in exons 18--21. On the basis of clinical assessment and further imaging studies, the patient was staged as stage IV lung cancer (cT2N0M1). The patient\'s performance status was 0 according to the Eastern Cooperative Oncology Group (ECOG) scale ([@b28-mco-0-0-1306]). The patient received a first-line chemotherapy with cisplatin (75 mg/m^2^) and PEM (500 mg/m^2^) every three weeks. Following four cycles of the treatment, a repeat CT scan revealed a PR ([Fig. 3A and B](#f3-mco-0-0-1306){ref-type="fig"}). The patient was followed with maintenance PEM monotherapy (500 mg/m^2^) for 12 courses. While continuing to show stable disease (SD), the patient subsequently received radiotherapy for the right upper lobe lung mass, and she was kept on PEM monotherapy with SD, with the exception of small right pleural effusion ([Fig. 3C and D](#f3-mco-0-0-1306){ref-type="fig"}).

In March 2015, following 18 months of first-line treatment, the patient again complained of right chest pain and discomfort. A CT scan revealed the recurrence of pleural effusion ([Fig. 4A and B](#f4-mco-0-0-1306){ref-type="fig"}), and the effusion specimen was re-evaluated for its pathological and molecular characteristics. In addition to malignant effusion, the cell-block material exhibited *ALK* gene rearrangement, which was confirmed by an automated immunohistochemistry (IHC) assay (Ventana pre-diluted ALK D5F3 antibody with the Optiview™ DAB IHC detection kit; Ventana Medical Systems, Inc., Tucson, AZ, USA) ([Fig. 5A](#f5-mco-0-0-1306){ref-type="fig"}), and by reverse transcription-quantitative polymerase chain reaction (RT-PCR) assay ([Fig. 5B](#f5-mco-0-0-1306){ref-type="fig"}). Notably, an *EGFR* mutation test performed on the current cell-block material revealed a deletion in exon 19 (delE746-A750; [Fig. 5C](#f5-mco-0-0-1306){ref-type="fig"}). Overexpression of EGFR protein was also observed by the IHC assay, using an antibody raised against EGFR (rabbit anti-human EGFR monoclonal antibody; cat. no. RMA-0554, Fuzhou Maixin Biotechnology Development Co. Ltd., Fujian, China) ([Fig. 5D](#f5-mco-0-0-1306){ref-type="fig"}).

After the molecular test results has been revealed, the patient started to receive treatment with gefitinib (250 mg, once daily). However, no clinical response was achieved, and a new pleura-based mass (dimensions, 3.0×3.0 cm) was identified after two months of gefitinib therapy ([Fig. 6A and B](#f6-mco-0-0-1306){ref-type="fig"}). A positron emission tomography (PET)-CT scan demonstrated multiple high metabolic lesions in the right upper lobe, the pleura, right ribs and in the liver under the capsule. In June 2015, the patient began to receive crizotinib (250 mg, twice per day), and she reported a rapid disappearance of discomfort and chest pain. After a further 6 months, the CT scan revealed a PR ([Fig. 6C and D](#f6-mco-0-0-1306){ref-type="fig"}). The patient remained asymptomatic at the last follow-up, in April 2016, and at present, she continues to receive crizotinib with the same dose.

This study was approved by the Ethics Committee of The First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China). Written informed consent was obtained from the patient\'s next of kin.

Discussion
==========

The prevalence of the coexistence of an *ALK* gene rearrangement and *EGFR* mutations may be variable, but it is generally low. Several studies have reported that the frequency ranges from 0--8% ([@b24-mco-0-0-1306],[@b29-mco-0-0-1306]). Recently, Ulivi *et al* reported that double mutations were detected in 6 of the 380 (1.6%) patients with non-small cell lung cancer (NSCLC) ([@b16-mco-0-0-1306]). Different frequencies may be associated with ethnic differences of the patients and the assay detection sensitivity ([@b13-mco-0-0-1306]). The optimal treatment, however, has yet to be elucidated, since the responses to EGFR and/or ALK inhibitors have proven to be conflicting ([@b3-mco-0-0-1306],[@b4-mco-0-0-1306],[@b9-mco-0-0-1306],[@b17-mco-0-0-1306],[@b19-mco-0-0-1306]).

Based on a review of the English literature, a total of 65 cases were identified, including the present case, with concomitant *EGFR* mutations and *ALK* gene rearrangement. The cases with *EGFR* mutations detected by sensitive detection methods, such as RT-PCR, targeted next-generation sequencing (NGS), and mutant-enriched NGS, as well as repetitions of the identical cases reported in different journals, were excluded. The patients\' clinicopathological characteristics and treatment outcomes are shown in [Tables I](#tI-mco-0-0-1306){ref-type="table"} and [II](#tII-mco-0-0-1306){ref-type="table"}. The patients included 32 women (49.2%) and 25 men (38.5%), with 9 (13.6%) patients of unknown sex. The mean age was 60 years old (ranging from 31--77 years). The patients of Asian ethnicity accounted for 56.9% (37 of 65) of the patients. The patients included 35 (56.9%) never smokers, 4 (6.2%) former smokers and 6 (9.2%) current smokers, with the smoking status unknown in 18 (27.7%) patients. The vast majority of patients (59 of 65 patients; 90.8%) were diagnosed with adenocarcinoma, with 35 cases (53.8%) being diagnosed at stages IIIb and IV. The *EGFR* mutations identified were exon 19 deletion in 34 (52.3%) and exon 21 (L858R) point mutation 19 (29.2%). *ALK* gene rearrangement was confirmed using fluorescence *in situ* hybridization (FISH) assay in 33 (50.8%) cases, by FISH and IHC in 9 (13.8%) cases, and by FISH and RT-PCR in 5 (7.76%) cases.

The efficacy of EGFR-TKI treatments for tumors that were double positive remains inconclusive. From the data presented in [Tables I](#tI-mco-0-0-1306){ref-type="table"} and [II](#tII-mco-0-0-1306){ref-type="table"}, it was noted that 39 (60.0%) patients had received an EGFR-TKI, 21 (53.8%) with gefitinib, 16 (41.6%) with erlotinib, and 2 (5.1%) with afatinib. Detailed information about the response to TKIs was provided for 36 patients. Among them, 26 (72.2%) patients showed a complete response (CR), PR, or SD (disease control rate, DCR), whereas a further 10 (27.8%) patients experienced progression of disease (PD). The median PFS of EGFR-TKIs was 11.9 months (ranging from 0.3--40 months) in 33 patients, which was similar to the PFS of EGFR-TKI treatment in patients who had the *EGFR* mutation alone. Zhao *et al* ([@b6-mco-0-0-1306]) reported a case of double positive mutations that benefited from a short period treatment of three TKIs. Baldi *et al* ([@b5-mco-0-0-1306]) described a case of a double positive NSCLC, in which a good clinical response was observed not only with erlotinib, but also with the ALK inhibitor, crizotinib. However, there are other studies that included double positive patients who did not respond to EGFR-TKIs, but achieved a good response to ALK inhibitors ([@b12-mco-0-0-1306],[@b13-mco-0-0-1306],[@b17-mco-0-0-1306]). As illustrated in our case, the patients received EGFR-TKI as a second-line therapy, but exhibited PD, including the occurrence of a new pleura-based mass. Subsequently, crizotinib was administered as a third-line treatment, which revealed a dramatic response. Similar results were reported by Lee *et al* ([@b17-mco-0-0-1306]). These authors reported a case of ALK-positive and EGFR-mutant NSCLC patient who did not respond to EGFR-TKI, but achieved a partial response to ALK inhibitors. From the literature review, only 15 (23%) patients received crizotinib treatment, the majority of whom had crizotinib selected for them as a second-line or third-line therapy. In 12 patients, the DCR was 93.3% and the median PFS was 10 months (0.4--25 months). Recently, Won *et al* ([@b13-mco-0-0-1306]) reported that EGFR-TKIs were not effective in double positive patients, whereas ALK inhibitors were efficient ([@b13-mco-0-0-1306]). In their study, the majority (7 of 8) patients treated with ALK inhibitors exhibited *EGFR* mutations by peptide nucleic acid-clamping RT-PCR and/or NGS, but not by Sanger sequencing, which may suggest the possibility of a low burden of *EGFR* mutants in these patients, although a complete explanation underpinning the lack of response to gefitinib remains unknown. Similarly, Sahnane *et al* ([@b19-mco-0-0-1306]) showed that patients with *ALK/EGFR* mutations might benefit from crizotinib, rather than erlotinib administration. In double positive patients, whichever target drug is more effective may depend on the levels of the two driver gene molecular alterations. From [Table II](#tII-mco-0-0-1306){ref-type="table"}, it was also noted that 12 patients had received chemotherapy, with the DCR being 75%. In the present case study, PEM therapy and crizotinib revealed a good response, and *ALK* gene rearrangement may have been the primary driven gene mutation. Park *et al* ([@b30-mco-0-0-1306]) demonstrated that *ALK*-positive patients had a greater response rate (RR) and longer PFS with PEM-based chemotherapy compared with the patients with *EGFR* mutations or without an *ALK* gene rearrangement. The RRs were 26.9, 12.8 and 18.5%, respectively; the PFSs were 7.8, 2.5 and 2.9 months, respectively.

The phenomenon of double positive mutations in NSCLCs may be explained by the heterogeneity of tumor cells: Different genetic alterations may occur in different tumor cells, or multiple oncogenic pathways may be altered in a single clone of tumor cells. Recently, Sahnane *et al* ([@b19-mco-0-0-1306]) reported the frequencies of mutant alleles and their gene dosage in double positive patients, suggesting that the *EGFR* mutation occurs as the first event, and *ALK* alterations, primarily identified in advanced lung adenocarcinomas, occur late during tumor progression.

With the introduction of precision-targeted therapy in NSCLC and the application of advanced molecular/genetic techniques, more double positive NSCLC patients would be identified. Won *et al* ([@b13-mco-0-0-1306]) detected four double positive cases in 1,458 cases of lung cancers for EGFR and ALK alterations by Sanger sequencing and the FISH technique, respectively. However, they identified additional 10 dual positive cases when more sensitive assays were used.

Repeat biopsies are crucial in managing patients with tumor recurrences. As in the present case study, the biopsies offered the opportunity to reassess the mutation profile, which is invaluable for choosing appropriate treatment options. Since the majority of patients with NSCLC are diagnosed through small samples, the tumor heterogeneity or relatively low number of tumor cells may lead to false negative results of *EGFR* mutations and *ALK* gene rearrangement. Hence, when obtaining small samples, it is crucial to maximize the number of samples available for molecular studies. Furthermore, in cases that tested positive for *EGFR* mutations, particularly when the tumors failed to respond to EGFR-TKI treatment, it is important to consider the possibility of double positive mutations, since *EGFR* mutations and *ALK* gene rearrangement do coexist in certain tumors.

In conclusion, in the present study, a case of lung adenocarcinoma with concomitant *EGFR* mutation and *ALK* gene rearrangement has been reported, which was refractory to gefitinib administration, but exhibited a good response to crizotinib and PEM chemotherapy. A review of the literature demonstrated that the frequencies of coexistence of *ALK* gene rearrangement and *EGFR* mutations ranged from 0--8%. Currently, there is no consensus standard therapy for tumors with double positive mutations. In cases with double positive mutations, the DCR of EGFR-TKI was reported to be 72.2%, with the PFS being 11.9 months, whereas the DCR of crizotinib was 93.3%, with the PFS being 10 months.

![Chest CT images recorded prior to treatment. (A and B) In September 2013, prior to treatment, a chest CT scan revealed a right upper lobe mass and right pleural effusion. CT, computed tomography.](mco-07-02-0173-g00){#f1-mco-0-0-1306}

![Pathological evaluation of the pleural effusion specimen. The cell-block specimen of pleural effusion revealed adenocarcinoma. (A) Hematoxylin and eosin staining (magnification, ×400). (B) Immunoperoxidase staining (magnification, ×400), showed positive for thyroid transcription factor-1.](mco-07-02-0173-g01){#f2-mco-0-0-1306}

![A repeat CT scan recorded after four cycles of PEM combined with cisplatin chemotherapy. (A and B) In December 2013, following four cycles of PEM combined with cisplatin chemotherapy, the response was considered as a partial response. (C and D) In December 2014, following 15 cycles of PEM maintenance therapy and radiotherapy of the right upper lobe lesion, a chest CT revealed stable disease, with the exception of small right pleural effusion. CT, computed tomography; PEM, pemetrexed.](mco-07-02-0173-g02){#f3-mco-0-0-1306}

![Chest CT images following 18 months of first-line treatment. (A and B) In March 2015, following 18 months of first-line treatment, a chest CT revealed right pleural effusion recurrence. CT, computed tomography.](mco-07-02-0173-g03){#f4-mco-0-0-1306}

![Re-evaluation of the effusion specimen for its pathological and molecular characteristics. (A) Positive ALK staining using a Ventana IHC assay (immunoperoxidase staining; magnification, ×400). (B) Positive *ALK* gene rearrangement using reverse transcription-polymerase chain reaction. (C) Presence of the *EGFR* mutation was revealed using the amplification refractory mutation system method. (D) Positive EGFR staining by IHC (immunoperoxidase staining, magnification ×400). IHC, immunohistochemistry; EGFR, epidermal growth factor receptor.](mco-07-02-0173-g04){#f5-mco-0-0-1306}

![Chest CT scans as the patient was administered treatments with gefitinib and crizotinib. (A and B) In May 2015, after 2 months\' treatment with gefitinib, a new mass was observed close to the right pleura. (C and D) Following the crizotinib treatment, the pleural mass was reduced in size, and considered as a partial response.](mco-07-02-0173-g05){#f6-mco-0-0-1306}

###### 

Patients with concomitant *EGFR* mutations and ALK fusion.

  Authors                                                          Patient Age/sex   Ethnicity   Smoker    Histology   TNM stage   EGFR mutation                  EGFR-TKI    Response   PFS (M)   ALK translocation   ALK-TKI      Response   PFS (M)   Chemotherapy     Response        (Refs.)
  ---------------------------------------------------------------- ----------------- ----------- --------- ----------- ----------- ------------------------------ ----------- ---------- --------- ------------------- ------------ ---------- --------- ---------------- --------------- -----------------------
  Miyanaga *et al*                                                 55/F              A           No        AC          IV          Del exon 19                    Gefitinib   SD         2         FISH, IHC, RT-PCR   Crizotinib   SD         4         Cis/Pem          SD              ([@b2-mco-0-0-1306])
  Chen *et al*                                                     56/M              A           Current   AC          IV          Del exon 19                    Erlotinib   SD         8         FISH, RT-PCR        Crizotinib   CR         22        Cis/Gem          NA (toxicity)   ([@b3-mco-0-0-1306])
  Chiari *et al*                                                   67/F              C           Νο        AC          IV          L858R exon 21                  Gefitinib   PR         27        FISH                Crizotinib   PR         25        Cis/Gem          SD              ([@b4-mco-0-0-1306])
  Baldi *et al*                                                    68/M              C           Νο        AC          IV          L858R exon 21                  Erlotinib   PR         37        FISH, IHC           Crizotinib   PR         10        Cis/Pem          SD              ([@b5-mco-0-0-1306])
  Zhao *et al*                                                     48/F              A           Νο        AC          IV          L861Q exon 21                  Erlotinib   SD         5.3       FISH                Crizotinib   SD         3.5       Ndp/Pem          PD              ([@b6-mco-0-0-1306])
  Zhou *et al*                                                     47/F              A           Νο        AC          IV          Del exon 19                    Gefitinib   PD         2         FISH, IHC           ND           NA         NA        Cis/Gem          PD              ([@b7-mco-0-0-1306])
  Tiseo *et al*                                                    48/M              C           Νο        AdSq        IV          Del exon 19                    Erlotinib   PD         NA        FISH                ND           NA         NA        Cis/Gem          PR              ([@b8-mco-0-0-1306])
  Popat *et al*                                                    65/F              C           Νο        AC          IIIa        Del exon 19                    Erlotinib   CR         25        FISH                ND           NA         NA        Carbo/Vin        PR              ([@b9-mco-0-0-1306])
  Tanaka *et al*                                                   39/M              A           Current   AC          IV          L858R exon 21                  Erlotinib   PD         1         RT-PCR, IHC         ND           NA         NA        Cis/Doc          SD              ([@b10-mco-0-0-1306])
  Jurgens *et al*                                                  69/M              C           Current   AC          IV          L861Q exon 21                  Gefitinib   PD         2         FISH                ND           NA         NA        Pem/Carbo/Beva   PR              ([@b11-mco-0-0-1306])
  Yang *et al*                                                     65/F              A           Νο        AC          IIIa        Del exon 19                    Erlotinib   PD         1.5       FISH, IHC           Crizotinib   PR         1.9       NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     54/F              A           Νο        AC          IV          Del exon 19                    Erlotinib   PR         12        FISH, IHC, RT-PCR   Crizotinib   SD         2.7       NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     65/F              A           Νο        AC          IV          exon 20 insertion              Afatinib    PR         5         FISH, IHC           Crizotinib   PD         0.4       NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     44/F              A           Νο        AC          IV          Del exon 19                    Gefitinib   PR         9         FISH, IHC, RT-PCR   NA           NA         NA        NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     40/M              A           Νο        AC          IV          Del exon 19                    Erlotinib   PR         17.5      FISH, IHC, RT-PCR   NA           NA         NA        NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     60/F              A           Νο        AC          IV          Del exon 19                    Afatinib    SD         7         FISH, IHC, RT-PCR   NA           NA         NA        NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     45/F              A           Νο        AC          IV          Del exon 19                    ND          NA         NA        FISH, IHC, RT-PCR   Crizotinib   PR         15.1      NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     56/F              A           Νο        AC          IV          L858R exon 21                  Gefitinib   PR         11.2      FISH, IHC, RT-PCR   NA           NA         NA        NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     66/F              A           Νο        AC          IV          L858R exon 21                  Gefitinib   PR         24.5      FISH                NA           NA         NA        NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     59/M              A           Νο        AC          IV          L858R exon 21                  Erlotinib   PR         13        FISH, IHC, RT-PCR   NA           NA         NA        NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     70/M              A           Νο        AC          IV          L858R exon 21                  Erlotinib   PR         27.4      FISH, RT-PCR        NA           NA         NA        NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     67/M              A           Νο        AC          IIIa        Del exon 19                    ND          NA         NA        FISH, IHC, RT-PCR   NA           NA         NA        NA               NA              ([@b12-mco-0-0-1306])
  Yang *et al*                                                     31/M              A           Current   AC          IV          K757R in exon 19               ND          NA         NA        FISH, RT-PCR        NA           NA         NA        NA               NA              ([@b12-mco-0-0-1306])
  Won *et al*                                                      73/M              A           Former    AC          IV          Del exon 19                    Gefitinib   PD         0.3       FISH, IHC           Crizotinib   PR         19        NA               NA              ([@b13-mco-0-0-1306])
  Won *et al*                                                      62/M              A           Νο        AC          IV          L861Q exon 21                  Gefitinib   SD         6         FISH                ND           NA         NA        NA               NA              ([@b13-mco-0-0-1306])
  Won *et al*                                                      49/M              A           Νο        AC          Ia          L858R exon 21                  ND          NA         NA        FISH                ND           NA         NA        NA               NA              ([@b13-mco-0-0-1306])
  Won *et al*                                                      68/F              A           Νο        AC          IV          E868K exon 21                  ND          NA         NA        FISH                ND           NA         NA        NA               NA              ([@b13-mco-0-0-1306])
  Kuo *et al*                                                      72/F              A           Νο        AC          IV          Del exon 19                    Gefitinib   PR         7         RT-PCR              ND           NA         NA        ND               NA              ([@b14-mco-0-0-1306])
  Xu *et al*                                                       71/F              A           Νο        AC          IV          Del exon 19                    Gefitinib   CR         8         FISH, RT-PCR        NA           NA         NA        NA               NA              ([@b15-mco-0-0-1306])
  Ulivi *et al*                                                    72/F              C           Νο        AC          NA          Del exon 19                    Gefitinib   CR         32        FISH                NA           NA         NA        NA               NA              ([@b16-mco-0-0-1306])
  Ulivi *et al*                                                    52/F              C           Former    AC          NA          Del exon 19                    Gefitinib   PR         10        FISH                NA           NA         NA        NA               NA              ([@b16-mco-0-0-1306])
  Ulivi *et al*                                                    41/M              C           Νο        AC          NA          Del exon 19                    Gefitinib   PD         2         FISH                NA           NA         NA        NA               NA              ([@b16-mco-0-0-1306])
  Ulivi *et al*                                                    73/F              C           Former    AC          NA          Del exon 19                    Erlotinib   PR         40        FISH                NA           NA         NA        NA               NA              ([@b16-mco-0-0-1306])
  Ulivi *et al*                                                    54/F              C           Current   AC          NA          L858R exon 21                  Gefitinib   PR         24        FISH                NA           NA         NA        NA               NA              ([@b16-mco-0-0-1306])
  Ulivi *et al*                                                    68/F              C           Νο        AC          NA          E746-S752\>S                   Gefitinib   PD         2         FISH                NA           NA         NA        NA               NA              ([@b16-mco-0-0-1306])
  Lee *et al*^[a](#tfn1-mco-0-0-1306){ref-type="table-fn"}^        NA/NA             A           NA        AC          IV          Del exon 19, A750P             Gefitinib   PD         0.3       FISH, IHC           Crizotinib   PR         9         NA               NA              ([@b17-mco-0-0-1306])
  Lee *et al*                                                      NA/NA             A           NA        AC          IIB         E746-A750 deletion             NA          NA         NA        FISH, IHC           NA           NA         NA        NA               NA              ([@b17-mco-0-0-1306])
  Lee *et al*                                                      NA/NA             A           NA        AC          IIIA        L718P                          NA          NA         NA        FISH, IHC           NA           NA         NA        NA               NA              ([@b17-mco-0-0-1306])
  Lee *et al*                                                      NA/NA             A           NA        AC          IA          L858R exon 21                  NA          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b17-mco-0-0-1306])
  Sasaki *et al*                                                   NA/NA             C           NA        NA          NA          Del exon 19                    Erlotinib   PR         5         FISH                NA           NA         NA        NA               NA              ([@b18-mco-0-0-1306])
  Sasaki *et al*                                                   NA/NA             C           NA        NA          NA          L858R exon 21                  Erlotinib   PR         9         FISH                NA           NA         NA        NA               NA              ([@b18-mco-0-0-1306])
  Sasaki *et al*                                                   NA/NA             C           NA        NA          NA          A767-V7-69dupASV               ND          NA         NA        FISH, IHC           NA           NA         NA        NA               NA              ([@b18-mco-0-0-1306])
  Sahnane *et al*                                                  74/M              C           Νο        AC          IIIB- IV    G719A                          Erlotinib   SD         8         FISH                Crizotinib   SD         NA        NA               NA              ([@b19-mco-0-0-1306])
  Sahnane *et al*                                                  67/M              C           Νο        AC          IIIB- IV    Del exon 19                    Erlotinib   PD         NA        FISH                Crizotinib   PR         NA        Carbo/Gem        NA              ([@b19-mco-0-0-1306])
  Sahnane *et al*                                                  51/F              C           Unknown   AC          IIIB-IV     L858R exon 21                  NA          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b19-mco-0-0-1306])
  Santelmo *et al*                                                 52/F              C           Current   AC          IIIA        Del exon 19                    Gefitinib   PR         NA        FISH                NA           NA         NA        NA               NA              ([@b20-mco-0-0-1306])
  Roossing *et al*^[b](#tfn2-mco-0-0-1306){ref-type="table-fn"}^   61/M              C           Νο        AC          IV          L862R                          NA          NA         NA        FISH, IHC           Crizotinib   PR         8         Carbo/Vin/Beva   PR              ([@b21-mco-0-0-1306])
  Cabillic *et al*                                                 65/M              C           NA        AC          NA          L858R exon 21                  Gefitinib   NA         NA        IHC                 NA           NA         NA        NA               NA              ([@b22-mco-0-0-1306])
  Cabillic *et al*                                                 62/M              C           NA        AC          NA          L858R exon 21                  Gefitinib   NA         NA        FISH                NA           NA         NA        NA               NA              ([@b22-mco-0-0-1306])
  Cabillic *et al*                                                 73/F              C           NA        NOS         NA          L858R exon 21                  Gefitinib   NA         NA        FISH                NA           NA         NA        NA               NA              ([@b22-mco-0-0-1306])
  Cabillic *et al*                                                 65/M              C           NA        AC          NA          L858R exon 21, T790M exon 20   NA          NA         NA        FISH                Crizotinib   PR         NA        NA               NA              ([@b22-mco-0-0-1306])
  Cabillic *et al*                                                 77/F              C           NA        AC          IV          Del exon 19                    NA          NA         NA        IHC                 NA           NA         NA        NA               NA              ([@b22-mco-0-0-1306])
  Cabillic *et al*                                                 52/M              C           NA        AC          NA          Del exon 19                    NA          NA         NA        IHC                 NA           NA         NA        NA               NA              ([@b22-mco-0-0-1306])
  Cabillic *et al*                                                 65/F              C           NA        AC          NA          Del exon 19                    NA          NA         NA        IHC                 NA           NA         NA        NA               NA              ([@b22-mco-0-0-1306])
  Cabillic *et al*                                                 68/M              C           NA        AC          NA          L858R exon 21                  NA          NA         NA        IHC                 NA           NA         NA        NA               NA              ([@b22-mco-0-0-1306])
  Zhu *et al*                                                      54/F              A           Νο        AC          NA          Del exon 19                    ND          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b23-mco-0-0-1306])
  Zhu *et al*                                                      61/F              A           Νο        AC          NA          Del exon 19                    ND          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b23-mco-0-0-1306])
  Zhang *et al*                                                    NA/F              A           NA        AC          NA          Del exon 19                    NA          NA         NA        RT-PCR              NA           NA         NA        NA               NA              ([@b24-mco-0-0-1306])
  Koivunen *et al*                                                 NA/NA             NA          NA        AC          I--III      Del exon 19                    NA          NA         NA        FISH, RT-PCR        NA           NA         NA        NA               NA              ([@b25-mco-0-0-1306])
  Kim *et al*                                                      69/F              A           Νο        AC          IV          Del exon 19                    NA          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b26-mco-0-0-1306])
  Kim *et al*                                                      64/M              A           Former    AC          I           Del exon 19                    NA          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b26-mco-0-0-1306])
  Kim *et al*                                                      47/M              A           Νο        AC          IV          Del exon 19                    NA          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b26-mco-0-0-1306])
  Kim *et al*                                                      74/F              A           Νο        AdSq        IV          L858R exon 21                  NA          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b26-mco-0-0-1306])
  Kim *et al*                                                      59/M              A           Νο        AC          IV          L858R exon 21                  NA          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b26-mco-0-0-1306])
  Wang *et al*                                                     NA/NA             A           NA        AC          NA          L858R exon 21                  NA          NA         NA        FISH                NA           NA         NA        NA               NA              ([@b27-mco-0-0-1306])
  Li *et al*                                                       55/F              A           Νο        AC          IV          Del exon 19                    Gefitinib   PD         2         IHC, RT-PCR         Crizotinib   PR         8         Cis/Pem          PR              The present study

The case has been described in Won *et al* ([@b13-mco-0-0-1306]), and was not calculated for the present study.

A case with EGFR, ALK and KRAS mutations in coexistence which were evaluated when the tumor relapsed. F, female; M, male; A, Asiatic; C, Caucasian; AC, adenocarcinoma; AdSq, adenosquamous; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; FISH, fluorescence *in situ* hybridization; IHC, immunohistochemistry; RT-PCR, real time-polymerase chain reaction; Del, deletion; NA, not available; ND, not done; Cis, cisplatin; Carbo, carboplatin; Doc, docetaxel; Gem, gemcitabine; Ndp, nedaplatin; Pem, pemetrexed; Vin, vinorelbine; Beva, bevacizumab; NACT, neoadjuvant chemotherapy; EGFR, epidermal growth factor receptor; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; TNM, tumor-lymph node-metastasis.

###### 

Characteristics of patients with concomitant *EGFR* mutation and ALK fusion (*n*=65).

  Characteristic                                     No. (%)
  -------------------------------------------------- ----------------
  Age (median, range)                                60 (31--77)
  Sex                                                
    Male                                             25 (38.5)
    Female                                           32 (49.2)
    Unknown                                          8 (12.3)
  Ethnicity                                          
    Asiatic                                          37 (56.9)
    Caucasian                                        27 (41.5)
    Unknown                                          1 (1.5)
  Smoking status                                     
    Non-smokers                                      37 (56.9)
    Former smokers                                   4 (6.2)
    Current smokers                                  6 (9.2)
    Unknown                                          18 (27.7)
  Histology                                          
    Adenocarcinoma                                   59 (90.8)
    Adenosquamous carcinoma                          2 (3.1)
    Not otherwise specified                          1 (1.5)
    Unknown                                          3 (4.6)
  TNM stage                                          
    I--IIIa                                          10 (15.4)
    IIIb-IV                                          35 (53.8)
    Unknown                                          20 (30.8)
  EGFR mutation                                      
    Del exon 19                                      34 (52.3)
    L858R exon 21                                    19 (29.2)
    L861Q exon 21                                    3 (4.6)
    Others                                           9 (13.8)
  ALK translocation                                  
    FISH                                             33 (50.8)
    FISH + IHC                                       9 (13.8)
    FISH + RT-PCR                                    5 (7.7)
    FISH + IHC+RT-PCR                                9 (13.8)
    IHC                                              5 (7.7)
    RT-PCR                                           2 (3.1)
    IHC + RT-PCR                                     2 (3.1)
  EGFR-TKI (n=39)                                    
    Gefitinib                                        21 (53.8)
    Erlotinib                                        16(41.6)
    Afatinib                                         2 (5.1)
  Response to EGFR-TKI (n=36)                        
    CR/PR/SD                                         26 (72.2)
    PD                                               10 (27.8)
    PFS of EGFR-TKI, months (median, range) (n=33)   11.9 (0.3--40)
  Response to ALK-TKI (crizotinib; n=15)             
    CR/PR/SD                                         14 (93.3)
    PD                                               1 (6.7)
  PFS of ALK-TKI, months (median, range) (n=12)      10 (0.4--25)
  Response to chemotherapy (n=12)                    
    CR/PR/SD                                         9 (75.0)
    PD                                               3 (25.0)

Del, deletion; EGFR, epidermal growth factor receptor; FISH, fluorescent *in situ* hybridization; IHC, immunohistochemistry; RT-PCR, real time-polymerase chain reaction; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; PFS, progression-free survival; TNM, tumor-lymph node-metastasis.

[^1]: Contributed equally
